Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Syros Pharmaceuticals Inc

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-17T21:00:00Z
VOLUME
904
Market Cap
0.01M

Momentum Score

…

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
-
Low
0.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.39M
Revenue Per Share
0.01
Gross Profit TTM
-88.25M
Debt / Equity
3.73
ROE
-776.96%
Net Debt
-77.45M
ROCE
-121.26%
Diluted EPS TTM
-3.07

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -164.57M -94.65M -86.56M -84.04M -75.44M
Net income -164.57M -49.30M -90.47M -85.83M -75.44M
Selling general administrative 28.28M 29.30M 23.04M 21.32M 21.48M
Gross profit 7.68M 14.88M 23.49M 15.09M 1.98M
Reconciled depreciation 2.25M 2.97M 3.02M 3.04M 2.72M
Ebit -159.45M -135.87M -99.42M -82.30M -77.74M
Ebitda -157.19M -130.77M -96.31M -78.84M -75.02M
Depreciation and amortization 2.25M 5.10M 3.10M 3.46M 2.72M
Non operating income net other - 45.35M - 0.05M 2.30M
Operating income -128.99M -135.87M -99.42M -82.30M -77.74M
Other operating expenses 138.92M 141.24M 122.91M 97.39M 79.72M
Interest expense 5.13M 4.13M 3.91M 1.79M 0.00M
Interest income 6.82M 2.13M 0.09M 0.43M -
Net interest income 1.69M -2.00M -3.82M -1.37M -
Income tax expense 2.08M -45.35M 3.91M 1.79M -2.30M
Total revenue 9.94M 14.88M 23.49M 15.09M 1.98M
Total operating expenses 30.77M 141.24M 122.91M 97.39M 79.72M
Cost of revenue 2.25M - - - -
Total other income expense net -35.59M 41.22M 12.86M -1.74M 2.30M
Net income from continuing ops -164.57M -94.65M -86.56M -84.04M -75.44M
Net income applicable to common shares - -94.65M -86.56M -84.04M -75.44M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 168.17M 244.49M 182.94M 213.25M 149.98M
Other current assets 5.45M 7.39M 3.24M 2.24M 2.65M
Total liab 151.51M 116.75M 97.72M 122.70M 70.79M
Total stockholder equity 16.66M 127.74M 85.22M 90.55M 79.18M
Deferred long term liab - - - - 1.63M
Other current liab 16.15M 17.97M 15.62M 11.08M 10.65M
Common stock 0.03M 0.02M 0.06M 0.06M 0.04M
Capital stock 0.03M 0.02M 0.06M 0.06M 0.04M
Retained earnings -722.81M -558.23M -463.58M -377.02M -292.98M
Other liab - 24.47M 3.03M 29.59M 22.64M
Other assets - 8.43M 6.03M 20.48M 3.58M
Cash 139.53M 167.47M 92.30M 173.98M 41.44M
Total current liabilities 36.68M 30.78M 31.51M 28.62M 23.52M
Current deferred revenue - 4.33M 10.18M 12.21M 5.74M
Net debt -77.45M -103.90M -27.11M -107.77M -15.52M
Short term debt 8.99M 2.07M 2.01M 1.73M 1.28M
Short long term debt 6.67M - - - -
Short long term debt total 62.08M 63.57M 65.19M 66.21M 25.92M
Other stockholder equity 739.44M 685.85M 548.82M 467.52M 372.10M
Property plant equipment - 11.35M 27.29M 14.21M 31.89M
Total current assets 144.98M 211.39M 136.59M 178.56M 114.51M
Long term investments - 0.00M 13.04M - -
Net tangible assets - 148.59M 106.06M 125.36M 79.18M
Short term investments 0.00M 34.84M 38.07M 0.00M 49.98M
Net receivables - 1.69M 2.98M 2.33M 20.16M
Long term debt 34.56M 40.65M 40.26M 39.55M -
Inventory - - - - 0.29M
Accounts payable 11.54M 6.41M 3.69M 3.60M 5.85M
Accumulated other comprehensive income - 0.10M -0.08M - 0.02M
Common stock total equity - 0.02M - 0.06M 0.04M
Retained earnings total equity - -558.23M - -377.02M -292.98M
Non currrent assets other 1.59M 8.43M 6.03M 5.05M 3.58M
Non current assets total 23.19M 33.09M 46.35M 34.69M 35.47M
Capital lease obligations 20.85M 22.92M 24.93M 26.66M 25.92M
Long term debt total - 40.65M - 39.55M 0.62M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 37.34M 68.43M -52.65M 50.00M 0.79M
Change to liabilities - 5.11M -11.86M -0.46M -2.08M
Total cashflows from investing activities 37.34M 67.19M -52.65M 46.66M -11.73M
Net borrowings -0.07M -0.29M -0.27M 39.38M -0.20M
Total cash from financing activities 43.46M 131.04M 70.51M 142.95M 65.99M
Change to operating activities - -3.72M 1.90M 1.61M 4.24M
Net income -164.57M -94.65M -86.56M -84.04M -75.44M
Change in cash -28.91M 75.17M -81.68M 132.25M -6.00M
Begin period cash flow 170.55M 95.39M 177.07M 44.82M 50.81M
End period cash flow 141.65M 170.55M 95.39M 177.07M 44.82M
Total cash from operating activities -109.71M -123.06M -99.54M -57.36M -60.25M
Issuance of capital stock 43.27M 119.76M 70.34M 102.27M 65.82M
Depreciation 2.25M 2.97M 3.02M 3.04M 2.72M
Other cashflows from investing activities 1.56M - - - 0.11M
Dividends paid 42.10M - - -0.43M -0.16M
Change to inventory - - 1.98M -2.53M -4.36M
Change to account receivables 1.69M 1.28M 0.01M 19.99M -20.16M
Sale purchase of stock 0.26M 0.22M 0.32M 0.43M 0.16M
Other cashflows from financing activities 0.26M 11.36M 0.44M 40.92M 5.01M
Change to netincome - -31.81M -6.10M 11.31M 9.84M
Capital expenditures 0.27M 1.24M 1.25M 3.34M 12.64M
Change receivables - - - 19.99M -20.16M
Cash flows other operating - -4.66M - -6.89M 26.02M
Cash and cash equivalents changes - 75.17M - 132.25M -6.00M
Change in working capital 5.05M -5.52M -10.60M 10.05M -3.48M
Stock based compensation 10.43M 11.41M 10.35M 10.94M 9.84M
Other non cash items 37.13M -37.27M 0.71M 2.32M 7.24M
Free cash flow -109.98M -124.31M -100.78M -60.70M -72.89M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SYRS
Syros Pharmaceuticals Inc
-
-%
0.00 - - 0.03 10.65 5.08 -0.41
NVO
Novo Nordisk A/S
-1.25
3.07%
39.45 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
536.45 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-9.75
1.02%
948.01 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Syros Pharmaceuticals Inc

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

35 CambridgePark Drive, Cambridge, MA, United States, 02140

617 744 1340

68

Name Title Year Born
Dr. Nancy A. Simonian M.D. Pres, CEO & Director 1961
Dr. Richard A. Young Ph.D. Scientific Founder, Member of Scientific Advisory Board & Director 1954
Mr. Jason Haas Chief Financial Officer 1968
Dr. David A. Roth M.D. Chief Medical Officer 1963
Dr. James E. Bradner M.D. Founder 1972
Dr. Nathanael S. Gray Ph.D. Scientific Founder & Member of Scientific Advisory Board NA
Dr. Eric R. Olson Ph.D. Chief Scientific Officer 1958
Courtney Solberg Mang. of Corp. Communications and Investor Relations NA
Mr. Gerald E. Quirk Esq., J.D. Chief Legal Officer 1968
Dr. Christian C. Fritz Ph.D. Head of Biology NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…